What Are Prebiotics and Probiotics?
Prebiotics are substrates (typically non-digestible carbohydrates) that are selectively utilized by host microorganisms, conferring a health benefit 1. They essentially serve as food for beneficial gut bacteria.
Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host 2. These are specific bacterial strains (most commonly Lactobacillus and Bifidobacterium species) that can modulate the gut microbiome.
Evidence for Routine Nutritional Use
For general daily nutritional advice in healthy individuals, there is insufficient evidence to recommend routine probiotic or prebiotic supplementation. The 2020 AGA guidelines specifically focused on disease-specific applications rather than general wellness, reflecting the lack of robust evidence for routine use in healthy populations 2.
The evidence base is characterized by:
- Significant strain-specificity (effects of one probiotic strain cannot be extrapolated to another)
- Heterogeneity in dosing, duration, and formulations across studies
- Most benefits demonstrated in specific disease states rather than general health promotion
- Very low to low quality evidence for most applications 2, 3
Clinical Practice Guideline Recommendations
Conditions Where Probiotics Are Conditionally Recommended:
1. Prevention of C. difficile Infection (CDI)
In adults and children on antibiotics, suggest using specific probiotic strains to prevent CDI 2:
- Saccharomyces boulardii
- 2-strain: L. acidophilus CL1285 + L. casei LBC80R
- 3-strain: L. acidophilus + L. delbrueckii subsp bulgaricus + B. bifidum
- 4-strain combination including S. salivarius subsp thermophilus
Strength: Conditional recommendation, Low quality evidence
Important caveat: Patients with severe illness or immunosuppression should avoid probiotics due to potential harm 2.
2. Pouchitis (Post-Colectomy for Ulcerative Colitis)
Suggest the 8-strain combination (L. paracasei subsp paracasei, L. plantarum, L. acidophilus, L. delbrueckii subsp bulgaricus, B. longum subsp longum, B. breve, B. longum subsp infantis, S. salivarius subsp thermophilus) for maintenance of remission 2.
Strength: Conditional recommendation, Very low quality evidence
Caveat: Only if cost and feasibility of obtaining this specific formulation is not prohibitive 2.
3. Necrotizing Enterocolitis (NEC) in Preterm Infants
In preterm infants <37 weeks gestational age, suggest specific strains 2:
- B. animalis subsp lactis
- L. reuteri (DSM 17938 or ATCC 55730)
- L. rhamnosus (ATCC 53103)
- Various combinations of Lactobacillus and Bifidobacterium species
Strength: Conditional recommendation, quality varies by strain
Conditions Where Probiotics Are NOT Recommended:
1. Irritable Bowel Syndrome (IBS)
Recommend probiotics ONLY in the context of clinical trials 2.
Rationale: Despite 76 RCTs examining 44 different strains, the evidence is marked by extreme heterogeneity, very low quality, small sample sizes, and significant publication bias. No consistent benefit demonstrated across formulations 2.
2. Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Recommend probiotics ONLY in the context of clinical trials 2.
Rationale: Insufficient evidence for induction or maintenance of remission. Studies limited by small sample sizes and heterogeneity 2.
3. Acute Infectious Gastroenteritis in Children
Suggest AGAINST the use of probiotics in North America 2.
Strength: Conditional recommendation, Moderate quality evidence
Critical distinction: While older studies from Europe and Asia showed benefit, two large high-quality multicenter trials from the United States and Canada showed no benefit, leading to this recommendation against use 2.
4. Active C. difficile Infection (Treatment)
Recommend probiotics ONLY in the context of clinical trials 2.
Rationale: Knowledge gap—insufficient evidence for treatment (as opposed to prevention) 2.
Key Clinical Pitfalls to Avoid
Strain-specificity is absolute: Benefits of one probiotic strain cannot be assumed for another, even within the same species 2. Always use the exact strain tested in clinical trials.
Safety concerns in vulnerable populations: Avoid probiotics in severely ill or immunocompromised patients due to risk of bacteremia or fungemia 2.
Geographic variation matters: Evidence from one region may not apply to another (as seen with pediatric gastroenteritis) 2.
Cost and availability: Many evidence-based formulations (particularly multi-strain combinations) may be difficult to obtain or prohibitively expensive 2.
Lack of regulation: Probiotic products are not consistently regulated, and viability of organisms in commercial products is often uncertain 2.
Summary of Evidence Quality
The overall evidence base for probiotics remains low to very low quality for most indications 2. The field is characterized by:
- Significant knowledge gaps requiring further research
- Inconsistent reporting of adverse effects
- Lack of standardization in manufacturing and strain identification
- Publication bias (many registered trials never published) 2
The AGA explicitly states that these guidelines will require updating within 3-5 years as new evidence emerges 2, underscoring the evolving and incomplete nature of current evidence.